Clinical outcomes and risk factors for local failure and visual impairment in patients treated with Ru-106 brachytherapy for uveal melanoma
Background and purpose: Small uveal melanomas are preferably treated with eye-sparing therapies such as brachytherapy or proton beam therapy. Knowledge of clinical outcomes and risk factors is important for personalized patient counselling. Materials and methods: Data of all choroidal melanoma patie...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | Clinical and Translational Radiation Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405630825000291 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850205099875368960 |
|---|---|
| author | L.J. Pors M. Marinkovic H.H. Deuzeman T.H.K. Vu E.M. Kerkhof K.M. van Wieringen-Warmenhoven C.R.N. Rasch J.C. Bleeker L.S. Koetsier J.W.M. Beenakker G.P.M. Luyten C.L. Creutzberg N. Horeweg |
| author_facet | L.J. Pors M. Marinkovic H.H. Deuzeman T.H.K. Vu E.M. Kerkhof K.M. van Wieringen-Warmenhoven C.R.N. Rasch J.C. Bleeker L.S. Koetsier J.W.M. Beenakker G.P.M. Luyten C.L. Creutzberg N. Horeweg |
| author_sort | L.J. Pors |
| collection | DOAJ |
| description | Background and purpose: Small uveal melanomas are preferably treated with eye-sparing therapies such as brachytherapy or proton beam therapy. Knowledge of clinical outcomes and risk factors is important for personalized patient counselling. Materials and methods: Data of all choroidal melanoma patients treated at the Leiden University Medical Center between 2012–2019 with Ruthenium-106 brachytherapy were collected. Time-to-event analyses were performed with the Kaplan-Meier method, risk factors for local failure and visual acuity (VA) decline were identified using Cox proportional hazards models with predefined covariates. Results: 719 patients were included. Median tumour prominence and diameter were 3.8 mm and 11.6 mm, respectively. 52 % of tumours were centrally located, and 19 % were juxtapapillary. Five-year overall survival, eye retention and local failure rates were 83 %, 95 %, and 8 %, respectively. Juxtapapillary location, lower tumour apex doses, and T3-4 tumour stage were significantly associated with local failure. Patients with juxtapapillary tumours had 20 % risk of local failure. Five years posttreatment, 47 % of patients had no functional visual impairment (Snellen VA ≥ 0.5). Lasting functional visual impairment was associated with baseline vision, central tumours, and scleral dose. Patients with central tumours had 75 % risk of mild or worse visual impairment after 5 years. Conclusion: Ruthenium-106 brachytherapy yields good local control and visual outcomes in patients with choroidal melanoma. Juxtapapillary tumours have a high risk of local failure and alternative therapies should be considered in these patients, if available. Patients with central tumours, and those with decreased pre-treatment vision should be counselled on the risk of visual impairment. |
| format | Article |
| id | doaj-art-79fbf4c8360c4739afa1bc801756842d |
| institution | OA Journals |
| issn | 2405-6308 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Clinical and Translational Radiation Oncology |
| spelling | doaj-art-79fbf4c8360c4739afa1bc801756842d2025-08-20T02:11:09ZengElsevierClinical and Translational Radiation Oncology2405-63082025-05-015210093910.1016/j.ctro.2025.100939Clinical outcomes and risk factors for local failure and visual impairment in patients treated with Ru-106 brachytherapy for uveal melanomaL.J. Pors0M. Marinkovic1H.H. Deuzeman2T.H.K. Vu3E.M. Kerkhof4K.M. van Wieringen-Warmenhoven5C.R.N. Rasch6J.C. Bleeker7L.S. Koetsier8J.W.M. Beenakker9G.P.M. Luyten10C.L. Creutzberg11N. Horeweg12Department of Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands; Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands; Corresponding author at: Leiden University Medical Center, Department of Radiation Oncology (K1-P), Postal box 9600, 2300RC Leiden, the Netherlands.Department of Ophthalmology, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Radiation Oncology, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Ophthalmology, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Radiation Oncology, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Radiation Oncology, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Radiation Oncology, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Ophthalmology, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Ophthalmology, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands; Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands; Department of Radiology, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Ophthalmology, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Radiation Oncology, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Radiation Oncology, Leiden University Medical Center, Leiden, the NetherlandsBackground and purpose: Small uveal melanomas are preferably treated with eye-sparing therapies such as brachytherapy or proton beam therapy. Knowledge of clinical outcomes and risk factors is important for personalized patient counselling. Materials and methods: Data of all choroidal melanoma patients treated at the Leiden University Medical Center between 2012–2019 with Ruthenium-106 brachytherapy were collected. Time-to-event analyses were performed with the Kaplan-Meier method, risk factors for local failure and visual acuity (VA) decline were identified using Cox proportional hazards models with predefined covariates. Results: 719 patients were included. Median tumour prominence and diameter were 3.8 mm and 11.6 mm, respectively. 52 % of tumours were centrally located, and 19 % were juxtapapillary. Five-year overall survival, eye retention and local failure rates were 83 %, 95 %, and 8 %, respectively. Juxtapapillary location, lower tumour apex doses, and T3-4 tumour stage were significantly associated with local failure. Patients with juxtapapillary tumours had 20 % risk of local failure. Five years posttreatment, 47 % of patients had no functional visual impairment (Snellen VA ≥ 0.5). Lasting functional visual impairment was associated with baseline vision, central tumours, and scleral dose. Patients with central tumours had 75 % risk of mild or worse visual impairment after 5 years. Conclusion: Ruthenium-106 brachytherapy yields good local control and visual outcomes in patients with choroidal melanoma. Juxtapapillary tumours have a high risk of local failure and alternative therapies should be considered in these patients, if available. Patients with central tumours, and those with decreased pre-treatment vision should be counselled on the risk of visual impairment.http://www.sciencedirect.com/science/article/pii/S2405630825000291Uveal melanomaBrachytherapyVisual acuityNeoplasm recurrence, Local |
| spellingShingle | L.J. Pors M. Marinkovic H.H. Deuzeman T.H.K. Vu E.M. Kerkhof K.M. van Wieringen-Warmenhoven C.R.N. Rasch J.C. Bleeker L.S. Koetsier J.W.M. Beenakker G.P.M. Luyten C.L. Creutzberg N. Horeweg Clinical outcomes and risk factors for local failure and visual impairment in patients treated with Ru-106 brachytherapy for uveal melanoma Clinical and Translational Radiation Oncology Uveal melanoma Brachytherapy Visual acuity Neoplasm recurrence, Local |
| title | Clinical outcomes and risk factors for local failure and visual impairment in patients treated with Ru-106 brachytherapy for uveal melanoma |
| title_full | Clinical outcomes and risk factors for local failure and visual impairment in patients treated with Ru-106 brachytherapy for uveal melanoma |
| title_fullStr | Clinical outcomes and risk factors for local failure and visual impairment in patients treated with Ru-106 brachytherapy for uveal melanoma |
| title_full_unstemmed | Clinical outcomes and risk factors for local failure and visual impairment in patients treated with Ru-106 brachytherapy for uveal melanoma |
| title_short | Clinical outcomes and risk factors for local failure and visual impairment in patients treated with Ru-106 brachytherapy for uveal melanoma |
| title_sort | clinical outcomes and risk factors for local failure and visual impairment in patients treated with ru 106 brachytherapy for uveal melanoma |
| topic | Uveal melanoma Brachytherapy Visual acuity Neoplasm recurrence, Local |
| url | http://www.sciencedirect.com/science/article/pii/S2405630825000291 |
| work_keys_str_mv | AT ljpors clinicaloutcomesandriskfactorsforlocalfailureandvisualimpairmentinpatientstreatedwithru106brachytherapyforuvealmelanoma AT mmarinkovic clinicaloutcomesandriskfactorsforlocalfailureandvisualimpairmentinpatientstreatedwithru106brachytherapyforuvealmelanoma AT hhdeuzeman clinicaloutcomesandriskfactorsforlocalfailureandvisualimpairmentinpatientstreatedwithru106brachytherapyforuvealmelanoma AT thkvu clinicaloutcomesandriskfactorsforlocalfailureandvisualimpairmentinpatientstreatedwithru106brachytherapyforuvealmelanoma AT emkerkhof clinicaloutcomesandriskfactorsforlocalfailureandvisualimpairmentinpatientstreatedwithru106brachytherapyforuvealmelanoma AT kmvanwieringenwarmenhoven clinicaloutcomesandriskfactorsforlocalfailureandvisualimpairmentinpatientstreatedwithru106brachytherapyforuvealmelanoma AT crnrasch clinicaloutcomesandriskfactorsforlocalfailureandvisualimpairmentinpatientstreatedwithru106brachytherapyforuvealmelanoma AT jcbleeker clinicaloutcomesandriskfactorsforlocalfailureandvisualimpairmentinpatientstreatedwithru106brachytherapyforuvealmelanoma AT lskoetsier clinicaloutcomesandriskfactorsforlocalfailureandvisualimpairmentinpatientstreatedwithru106brachytherapyforuvealmelanoma AT jwmbeenakker clinicaloutcomesandriskfactorsforlocalfailureandvisualimpairmentinpatientstreatedwithru106brachytherapyforuvealmelanoma AT gpmluyten clinicaloutcomesandriskfactorsforlocalfailureandvisualimpairmentinpatientstreatedwithru106brachytherapyforuvealmelanoma AT clcreutzberg clinicaloutcomesandriskfactorsforlocalfailureandvisualimpairmentinpatientstreatedwithru106brachytherapyforuvealmelanoma AT nhoreweg clinicaloutcomesandriskfactorsforlocalfailureandvisualimpairmentinpatientstreatedwithru106brachytherapyforuvealmelanoma |